Immune reactions in the tumor micro-environment are one of the cancer hallmarks and emerging immune therapies have been proven effective in many types of cancer. To investigate cancer genomeimmune interactions and the role of immuno-editing or immune escape mechanisms in cancer development, we analyzed 2,834 whole genomes and RNA-seq datasets across 31 distinct tumor types from the PanCancer Analysis of Whole Genomes (PCAWG) project with respect to key immunogenomic aspects. We show that selective copy number changes in immune-related genes could contribute to immune escape. Furthermore, we developed an index of the immuno-editing history of each tumor sample based on the information of mutations in exonic regions and pseudogenes. Our immuno-genomic analyses of pan-cancer analyses have the potential to identify a subset of tumors with immunogenicity and diverse background or intrinsic pathways associated with their immune status and immuno-editing history.
Genomic instability and inflammation or immune responses in the tumor microenvironment are major underlying hallmarks of cancer (Hanahan and Weinberg, 2011) , and the interaction between the cancer genome and immune reactions could have important implications for the early and late phases of cancer development. The immune system is a large source of genetic diversity in humans and tumors (Lefranc et al., 1999) . Human leukocyte antigen (HLA), the vast number of unique T-and Bcell receptor genes, and somatic alterations in tumor cell genomes enable the differentiation between self and non-self (tumor) via neoantigen (NAG) presentation, which contributes to positive or negative immune reactions related to cancer (Linnemann et ; however, most cancers are still resistant to these immunotherapies. Even after successful treatment, tumors often acquire resistance via another immune escape mechanism or by acquiring genomic mutations in instinct signaling pathways, such as the IFN gamma pathway or MHC (HLA) presentation pathway, related to NAG (Gao et al., 2016; Shin et al., 2017) . Tumor aneuploidy is also correlated with immune escape and the response to immunotherapy (Dovoli et al., 2017); hence, a comprehensively understand cancer immunology and its diversity by whole genome analyses is necessary. We here analyzed the whole genome sequencing (WGS) of 2,834 donors and RNA-seq data from PanCancer Analysis of Whole Genomes (PCAWG) project (Campbell et al., PCAWG marker paper, and Yung et al., PCWG Tech paper) with respect to key immunogenomic aspects using computational approaches (Hackl et al., 2016 ). Our results demonstrate that diverse genomic alterations in specific tumor types, variation in immune microenvironments, and variation in oncogenic pathways are related to immune escape, and we further observed immune editing during cancer development. To illustrate the history of immunoediting history for each cancer genome and to explore underlying molecular pathways involved, we defined immuno-editing indexes (IEIs) by comparing exonic NAGs to virtual NAGs in pseudogenes.
Somatic alterations in immune-related genes may contribute to cancer development and progression or immune escape in certain solid tumors and hematopoietic tumors. To investigate the extent of such genomic alterations, we compiled a list of 267 immune-related genes (Supplementary Table 1 ) that could be assigned to four categories: the immune escape pathway, antigen presentation pathways for HLA class I and HLA class II, and the cytokine signaling and apoptotic pathways, including genes involved in the IFN gamma pathway. An analysis of PCAWG consensus variant calls (Yung et al. , PCWG Tech paper) demonstrated that most tumor samples have at least one somatic alteration in these immune-related genes (Figure 1a) . Although copy number alterations (CNAs) were the most frequently detected type of somatic alteration, many point mutations and structural variants (SVs) were also detected in the immune-related genes. We first examined the relationship between the somatic mutations in immune-related genes and the total number of somatic mutations, especially for nonsynonymous mutations. Consistent with previous observations (Marty et al., 2017) , we observed that tumors with B2M mutations carried more nonsynonymous mutations than tumors without B2M mutations (p = 2.6E-12). Furthermore, this trend was more profound for samples with either B2M mutations or HLA mutations (p = 1.6E-21) (Figure 1b) . We also analyzed the number of nonsynonymous mutations in tumor samples showing reduced copy numbers of genes in the antigen presentation pathway, i.e., HLA-A, HLA-B, HLA-C, B2M, TAP1, TAP2, and TAPBP. Tumors with copy number losses also had more nonsynonymous mutations (p = 0.0162), further supporting the notion that the loss of functions of genes involved in antigen presentation genes leads to an increase in nonsynonymous mutations, presumably due to compromised immune pressure.
We also investigated SVs in immune-related genes. Although SVs are relatively rare compared to CNAs, they may have a large impact on the expression and function of affected genes, as exemplified by a recent report of the 3′-untranslated region of CD274/PD-L1 (Kataoka et al., 2016) . For each immune-related gene, we compared mRNA expression levels between SV-positive and SV-negative cases. For ten immune-related genes (CD274/PD-L1, PDCD1LG2/PD-L2, MARCH9, IL22, SEC61G, CCND1, CCT2, INHBC, AKT3, and SOCS7), we detected a statistically significant association between the occurrence of SVs and the upregulation of expression (q-value < 0.05; Figure 1c As shown in Figure 1a , CNAs are the most frequently observed alterations in immune-related genes. Cancers harboring many CNAs tended to show less immune involvement and worse responses to immunotherapies (Davoli et al., 2017) , and this can potentially be explained by CNAs in immunerelated genes. We next compared the copy numbers of immune-related genes with the ploidy levels of tumors to differentiate between selective increases in copy number or changes in ploidy or averaged changes of chromosomes. We first focused on interleukin-10 (IL10), an immune suppressor gene (Itakura et al., 2011) . IL10 expresses not only immune cells, but also tumors; the functions of IL10 produced from tumor cells were mainly reported in melanoma (Wiguna and Walden, 2015) . We then examined the differences between copy number of IL10 and ploidy level for each donor of multiple tumor types (Figure 1d) . In Liver-HCC, Breast-AdenoCA, Skin-Melanoma, and Lung-AdenoCA samples, the IL10 copy number was specifically increased, rather than the ploidy level, in almost all tumors. Since IL10 functions as a repressor of immune cells, the amplification or gain of IL10 is possibly related, in part, to the immune escape mechanism. However, in Kidney-ChRCC, no significant selective amplification was observed.
We analyzed other immune-related genes and tumor types, including MSI (microsatellite instability)-positive tumors (Fujimoto, PCAWG-7, et al., in preparation) with strong immunogenicity (Le et al., 2015) due to high numbers of NAGs. For each immune-related gene, we used t-tests to evaluate whether the copy number differences from the ploidy level are significant or not in each tumor type. The results are summarized as a landscape of selective copy number changes in Figure 1e (showing the mean copy number changes against the ploidy value) and Supplementary Figure 2 (showing the statistical significance of selective copy number changes). TGFB2 and IL10 are located on chromosome 1q and both function as suppressors of immune cells (Wiguna and Walden, 2015; Yang et al., 2015) , and the selective copy number gains for these immune genes are likely to be related to tumor-immune system interactions (Figure 1e) . Recently, a molecule inhibiting TGFB2 and PD-L1 simultaneously is reported its efficacy (Lan et al., 2018; Strauss et al., 2018) , it might be important to know an immune escape mechanism related to TGFB2. SEC61G and MARCH9, both of which exhibited significant overexpression related to SVs (Figure 1c) , showed different patterns from those of TGFB2 and IL10. MARCH9 showed statistical significance in some tumor types; considering the mean value of the differences in each tumor type, selective copy number gain was detected in CNS-GBM and Bone-Leiomyo. Additionally, SEC61G was selectively amplified in CNS-GBM and Head-SCC. Interestingly, donors with SV-related overexpression and donors with selective copy number gains were highly correlated; however, selective copy number gain could only partially explain the overexpression of these genes for the donors without SVs (Supplementary Figure 3) .
In Skin-Melanoma, the copy numbers of genes on chromosome 6, including HLAs, were significantly greater than the ploidy level (p = 2.26E-10 for HLA-A), which could paradoxically enforce immune pressure. However, the copy number of IL10 was also significantly (p = 8.1E-10) and selectively increased, potentially contributing to escape from immune pressure. By contrast, in Kidney-ChRCC and Panc-Endocrine samples, the copy numbers of HLAs compared with the ploidy level show the opposite tendency, and IL10 follows this. Since HLAs are not selectively increased, the copy number gain for IL10 may be unnecessary for immune escape. In Lymph-NOS and Myeloid-MDS, copy numbers of almost all immune genes were consistent with ploidy and were not selectively changed (minimum p = 0.498 and 0.184 for Lymph-NOS and Myeloid-MDS, respectively). MSI tumors showed weak selective copy number increases for genes in the cluster including IL10 (p = 0.000644); however, significant results were not obtained for other immune-related genes. In these tumor types, there may exist different immune escape systems, other than the selective copy number gain of these immune genes.
We identified two possible explanations for copy number gains, i.e., they occurred during the process of ploidy formation or they occurred by a selective process during tumorigenesis. We analyzed the differences between copy number and ploidy and, interestingly, found that genomic regions containing genes that function as suppressors of the immune system, such as TGFB2 and IL10, are selectively increased in many types of tumors. Copy number gains of these immune-related genes could arise and be selected during the establishment of immune escape. Therefore, selective copy number gains may be involved in the history of immune escape. Since TGFB2 and IL10 could play important roles in immune escape based on their function, our findings indicate that selective copy number gain is a remarkable system in the mechanism of immune escape. However, no selective copy number gains were observed in immune checkpoint genes, i.e., PD-L1 and PD-L2, which function as part of the immune escape mechanism, further supporting the diversity of immune escape mechanisms. (Figure 2b ) (Burnet, 1970; Dunn et al., 2002) . To estimate the strength of immune surveillance or immune pressure experienced by tumor cells in each sample, we developed a novel approach to measure the strength of immune pressure using pseudogenes as an internal control (Figure 2a ) (see Methods). First, we identified predicted NAGs from somatic substitutions in exonic regions of whole genome sequences and compared them to those similarly derived from pseudogenes (Supplementary Figure 4) . In this process, we used the HLA types (class I and II, shown in Supplementary Figure 5 ) determined by our new pipeline, referred to as ALPHLARD (see Methods). The accumulation of somatic mutations in exonic regions versus virtual somatic mutations in pseudogenes during tumorigenesis is schematically represented in Figure 2b . If tumor cells grew under strong immune pressure, the difference between predicted NAGs in exonic and pseudogene regions would be large. This difference is expected to be small if tumor cells immediately escape from immune pressure in the carcinogenic process (Figure 2c) . We defined the immuno-editing index (IEI) according to this concept (see Methods). The virtual neoantigen ratio RP for mutations in pseudogene regions and the neoantigen ratio RE for exonic regions can be plotted (Figure 2d ) to determine the immune pressure for each tumor sample. IEI is defined as the log-ratio of RP to RE. We used IEI to characterize the histories of different donors, including immuno-edited and immuno-editing-resistant tumors.
In subsequent analyses, we investigated the history of immune pressures for multiple tumor types, as revealed by IEI. The distributions of immune pressure for four cancers are shown in Figure 2e . The percentage of IEI-positive samples, i.e., immune-editing-resistant tumors, in each tumor is shown in Figure 2f . MSI-positive tumors show immuno-edited tumor characteristics, suggesting that MSIpositive tumors continuously fought against immune pressure and eventually escaped. Bladder-TCC, Stomach-AdenoCA, Lymph-BNHL and Head-SCC samples showed immuno-editing-resistant tendencies, indicating that mutations generating NAGs were removed by negative selection during tumorigenesis.
We compared the IEI values with the ploidies using pan-cancer data and observed a significant negative correlation (Pearson's correlation coefficient, r = -0.13, p = 0.0051) (Figure 2g) . Among the tumor types, the strongest correlation was observed in Lung-AdenoCA (r = -0.66, p = 0.00028), and multiple tumor types, including ColoRect-AdenoCA, Eso-AdenoCA, and Skin-Melanoma, showed weak negative correlations, although these were not statistically significant. The negative correlation between IEI and ploidy can likely be attributed to the scenario in which a copy number gain leads to high expression of NAGs and thus high immune pressure.
We next examined the immune characteristics or signatures related to the difference in immune escape histories (as determined by IEI). Differentially expressed genes between IEI-positive andnegative tumors were analyzed to find acquired phenotypes or micro-environmental characteristics that promote tumor cell escape from immune pressure. Using four signatures related to immune characteristics, i.e., HLA class I, cytotoxic, immune checkpoint, and cell component, we divided samples into two groups, referred to as hot (inflamed) and cold (non-inflamed) tumors, and we further used gene set enrichment analyses (GSEA) to elucidate the pathways associated with IEI stratification (Supplementary Figure 6) . The genes related to each of above four signatures are listed in Supplementary Table 2. Interestingly, we found distinct patterns of gene set enrichment in the highexpression and low-expression groups (Supplementary Figure 7) . In the high-expression groups, multiple gene sets, e.g., interferon gamma response and inflammatory response genes, were commonly enriched in most tumor types (Supplementary Figure 7) . In contrast, in the lowexpression groups, most gene sets were differentially enriched in a tumor-specific manner. Thus, immune escape pathways preventing immune-cell infiltration are diverse and specific to each tumor type.
Furthermore, we specifically examined the degree of enrichment of four specific gene sets with respect to IEI (for gene sets of interferon gamma response, EMT (epithelial to mesenchymal transition) (Terry et al., 2017), TGF beta signaling (Yang et al., 2015) , and WNT/β-catenin signaling (Spranger et al., 2014 ; Pai et al., 2017)) (Figure 3a) . The interferon gamma response gene set was enriched in inflamed tumors of all tumor types, as expected, as the expression levels of these genes are higher in inflamed tumors than in non-inflamed tumors. Using IEI, this trend was maintained in Head-SCC, Lung-AdenoCA, Lung-SCC, and Lymph-BNHL samples; in these tumor types, those genes are more highly expressed in the IEI-positive group than in the IEI-negative group. However, in Skin-Melanoma, the enrichment of this gene set was not significant, while these genes were significantly underrepresented in four tumor types (Bladder-TCC, ColoRect-AdenoCA, StomachAdenoCA, and Uterus-AdenoCA). This suggests that the diversity of immuno-editing histories depends on the tumor type. For the EMT gene set, the four immune signatures are also highly consistent in some types of tumors, such as Bladder-TCC, Lung-SCC, and Skin-Melanoma, and EMT may have important roles in the immune microenvironment in these tumors (Hugo et al., 2016; Chae et al., 2018). For the TGFβ signaling gene set, diverse associations with the four immune signatures were detected. WNT/β-catenin signaling was inversely related to these immune signatures and IEI in several tumor types, such as Skin-Melanoma. In Lung-AdenoCA, Lung-SCC, Lymph-BNHL, and Skin-Melanoma, the trends in IEI seemed to be consistent with the four immune signatures. Finally, we performed a survival analysis of donors partitioned by IEI values and found that LungAdenoCA cancer donors with IEI-positive tumors (immuno-editing resistant tumor) exhibited a much worse overall survival than that of donors with IEI-negative tumors. In Lung-AdenoCA, IEI showed significant separation (p = 0.011, Figure 3c ), whereas those for the other aforementioned gene set signatures were not significant. We also analyzed the relationship between selective copy number gain (IL10 and TGFB2) and overall survival and showed three examples using Liver-HCC, LungAdenoCA, and Cervix-SCC. For these tumor types, tumors with selective copy number gains of IL10 or TGFB2 showed worse overall survival than that of the tumors without these copy number gains (p = 0.0551 for the liver, p = 0.1 for the lung, and p = 0.0202 for the cervix).
CONCLUSION
We derived immuno-genomic profiles, including somatic mutations in immune genes, HLA genotypes, NAGs, and immune micro-environmental landscapes, from pan-cancer whole genome and RNA sequence data. We observed that tumors acquired many types of immune escape mechanisms by selective copy number gains of immune-related genes, failure of the antigen presentation system, and alterations in immune checkpoint molecules in a tumor-specific manner. The history of immunoediting, as estimated using pseudogenes as sites free of immune pressure, indicated associations between tumorigenesis and immune escape across various tumor types. Furthermore, the microenvironmental landscape related to immune characteristics revealed diverse background or intrinsic pathways controlling the non-inflamed subset of each tumor type. This provides essential information for identifying therapeutic targets. These analyses revealed the impact of the immune microenvironment on the immune resistance and/or immune escape of tumors. Table 2 and the expression of genes in two groups of samples were compared using two-sided t-tests. The enrichment of gene sets defined by MSigDB was evaluated by GSEA. The score is defined in the same way as selective copy number changes, using the sign of the enrichment score and its p-value. 
Supplementary

METHODS
Genomic alterations in immune-related genes in pan-cancer datasets
Datasets of somatic point mutations, structural variants (SVs), and copy number alterations were generated as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) project. Overall, 2834 samples with whole genome data are represented in the PCAWG datasets, spanning a range of cancer types (bladder, sarcoma, breast, liver-biliary, cervix, leukemia, colorectal, lymphoma, prostate, esophagus, stomach, central nervous system, head/neck, kidney, lung, melanoma, ovary, pancreas, thyroid, and uterus). The consensus somatic SVs, CNAs, and SNVs in PCAWG samples were determined by three different data centers using different algorithms; calls made by at least two algorithms were used in downstream analyses. To determine copy number, the calls made by the Sanger group were used (Yang et al., PCAWG Tech paper)
HLA genotyping and mutations from whole genome sequences For HLA genotyping using whole genome sequencing data, a Bayesian method known as ALPHLARD was used; this method was designed to perform accurate HLA genotyping from shortread data and to predict the HLA sequences of the sample. The latter function enables the identification of somatic mutations by comparisons of the HLA sequences of the tumor sample with those of the matched-normal sample. The statistical formulation for the posterior probability can be described as follows:
, where R = (R1, R2) is the pair of HLA types (reference sequences), S = (S1,S2) is the pair of HLA sequences of the samples, X = (x1, x2,...) is the set of sequence reads, and I = (I1, I2,...) is the set of variables taking 1 or 2 (the jth element, Ij indicates the jth read xj is generated from). On the righthand side of the above equation, the left term indicates the likelihood of the sequence reads when the HLA sequences and the reference sequences are fixed. The middle and the right terms are the priors. The parameters, HLA sequences, and HLA types, were determined using the MCMC procedure with parallel tempering.
Immune signatures from RNA-seq data
To investigate the microenvironment related to the immune characteristics of tumors, the following immune-related signatures were prepared (Supplementary Table 2 Cell component Using a signature, two subsets of samples were defined, a subgroup of samples with immune characteristics indicating the focused signature, and a subgroup lacking these characteristics. By comparing RNA expression levels in these subgroups, enriched gene sets or pathways were identified as related microenvironments.
Immuno-signature-based GSEA For each cancer type, the samples were divided into two groups based on gene expression patterns of an immuno-signature set, e.g., cytotoxic signature set, and a GSEA was conducted for gene sets using MSigDB by comparing whole gene expression values between the two groups of samples. To obtain the two groups, hierarchical clustering was applied to the gene expression matrix for immunosignature genes of the samples and the dendrogram for the samples was cut at the root. The group with a higher mean expression value for immuno-signature genes than that in the other group was labeled "High," while the other was labeled "Low." In this study, as described above, we considered four immuno-signature sets. For an immuno-signature set, the above GSEA was applied for each cancer type and the enrichment results for MSigDB gene sets were compiled into heatmaps. In a heatmap, each cell corresponds to a pair of an MSigDB gene set and cancer type, and has the value of, where the nominal p-value and is an indicator variable; if the gene set is enriched in "High" group and otherwise (Supplementary Figure 6) .
Immune cell components
For CIBERSORT implementation, FPKM values were used after upper-quartile normalization as input gene expression values (FPKMs are in linear space, without log-transformation) and the default LM22 was used as the signature gene matrix. Twenty-two leukocyte fractions were imputed from CIBERSORT. Originally, CIBERSORT was proposed for RNA expression data obtained by microarray. However, it has been reported that CIBERSORT can be applied to bulk tumor RNA-seq (Tuong et al., 2016; Mehnert et al., 2016) and single-cell RNA-seq (Baron et al., 2016) . The correlation between results obtained using microarray data and RNA-seq data from 166 LAML-US tumors was independently evaluated; the observed correlation coefficient was 0.93, which was significantly high. Therefore, CIBERSORT was applied to RNA-seq data (Supplementary Figure 9) .
Neo-antigen prediction
From PCAWG preliminary consensus files, 2,786 annotated .tsv files were generated using ANNOVAR and exclusion samples were removed according to release_may2016.v1.3.tsv. Next, focusing on nonsynonymous mutations in exonic regions, the corresponding mutant/wild-type peptides of length 8-11-mer including an amino-acid substitution were constructed using the UCSC RefSeq mRNA and refFlat data (http://hgdownload.soe.ucsc.edu/downloads.html). Next, binding affinities (IC50) of all generated peptides were predicted using netMHCpan3.0 (Nielsen and Andreatta, 2016) for HLA class I and netMHCIIpan3.1 (Andreatta et al., 2015) for HLA class II. Finally, neoantigens were counted for each patient by considering that mutant peptides with IC50 values of less than 500 as neoantigens. Here, neoantigens were counted as the number of mutations that can generate neoantigens; thus, each mutation was counted once, even if it generated more than one neoantigen for one or more HLAs. Note that mutations in which annotated information was not consistent with UCSC RefSeq mRNA and refFlat data were skipped as database mismatches. The ratio of the number of non-skipped nonsynonymous mutations to the number of all observed nonsynonymous mutations was defined as the concordance rate. Although this value was nearly 1 in all cases (greater than 0.99, on average), it was used as a tuning parameter, as described below.
Immuno-editing index
To evaluate the sample-specific immuno-editing history, an immuno-editing index (IEI) describing the degree of accumulated immune suppression was established. IEI compares the ratio of the number of neoantingens to the number of nonsynonymous mutations in exonic regions and in the control regions, which are not affected by immune pressure. Pseudogene regions were used as internal controls for a tumor and only pseudogene mutations whose genomic positions were downstream of the stop codon were extracted according to PseudoPipe v.74 (http://www.pseudogene.org/pseudopipe/). In this concept, the following assumptions were made: (i) nonsynonymous mutations in exonic regions can be suppressed by immune pressure if their mutant peptides can bind to HLAs and (ii) synonymous mutations in exonic regions and nonsynonymous/synonymous mutations in pseudogene regions are not affected by immune pressure. Under these assumptions, the number of nonsynonymous mutations in exonic regions can be lower than the number of ideal nonsynonymous mutations in exonic regions, indicating the hypothetical number of nonsynonymous mutations under non-immune pressure. Several quantities were defined as follows:
・ Number of nonsynonymous mutations used to evaluate neoantigens (not skipped by database mismatch) in exonic regions = #nonsynE ・ Number of synonymous mutations in exonic regions = #synE ・ Number of predicted neoantigens in exonic regions = #NagE ・ Number of nonsynonymous mutations used to evaluate neoantigens (not skipped by database mismatch) in pseudogene regions = #nonsynP ・ Number of synonymous mutations in pseudogene regions = #synP ・ Number of predicted neoantigens in pseudogene regions = #NagP ・ Concordance rate of mutation annotations in exonic regions = -./0 ・ Concordance rate of mutation annotations in pseudogene regions = 12-34/ The number of nonsynonymous mutations in exonic region was adjusted to obtain the number of ideal nonsynonymous mutations (#InonsynE) using the above quantities as follows:
Here, #InonsynE was set to #NagE if #InonsynE was less than #NagE. IEI was calculated as the modified log ratio in terms of the numbers of neoantingens and nonsynonymous mutations, and is equal to the sum of the numbers of neoantingens and nonneoantingens between exonic and pseudogene regions as follows:
where C is a regularized constant, set to 0.5 for the analysis.
Pseudogene selection
PseudoPipe (build 74) (Zhang et al., 2006) was used as a pseudogene database for the following analysis, which includes the region and the parental gene of each pseudogene, among other information. First, pseudogene mutations in each sample were extracted from the VCF file based on pseudogene regions described in PseudoPipe. Next, each pseudogene in PseudoPipe was aligned to the parental gene using Clustal Omega (version 1.2.1) (Sievers et al., 2011) with default settings. Each pseudogene mutation was converted to a parental gene mutation located at the same position as that of the pseudogene mutation in the alignment. Note that pseudogene mutations were excluded in the following neo-antigen analysis if the position corresponded to an intron of the parental gene or if the bases differed at the position in the alignment of the pseudogene and the parental gene. Thus, except for the above cases, pseudogene mutations were treated as if they were exonic mutations. An immuno-editing history analysis was applied to the converted mutations and the results were used as an internal control. Mutations in pseudogene regions were used directly, without information for parental genes. However, the amino acid composition in pseudogene regions with parental genes is considered similar to that in exonic regions. Additionally, in pseudogene regions, many stop codons are present and a method was determined to handle these. Therefore, pseudogene regions with parental genes were used as a suitable internal control to evaluate the strength of immune pressure. TNFRSF6B  BIRC7  CD40  BCL2L1  EBAG9  CCL28  SIRPA  KRAS  IL6  CYCS  PVRIG  NOS3  CASP2  KLRB1  KLRD1  KLRG1  KLRF1  KLRC1  KLRC2  KLRK1  CD27  TAPBPL  TNFRSF1A  LAG3  GAPDH  BTLA  CD200  CD200R1  CD96  NECTIN3  TIGIT  CD47  HHLA2  CD86  CD80  SEC61A1  CCL5  CCL2  CCL3  LGALS9  NOS2  PSME3  BIRC5  MPO  CSF3  TNFRSF12A  LILRB1  KIR3DL3  KIR2DL3  LILRB2  BIRC8  KIR2DL1  KIR2DL4  KIR3DL2  KIR3DL1  BAX  CEACAM1  CXCL17  TGFB1  NECTIN2  PVR  PSMB9  TAP1  PSMB8  HLA−DOB  TAP2  HLA−DMB  HLA−DMA  HLA−DOA  HLA−DQA2  HLA−DPB1  HLA−DPA1  TAPBP  HLA−F  HLA−G  HLA−A  HLA−E  BTN3A1  BTN2A2  BTN1A1  MICA  HLA−B  MICB  HLA−C  TNF  LTA  HLA−DQB1  HLA−DQA1  HLA−DRB1  BTNL2  HLA−DRA  SERPINB9  RIPK1  VEGFA  TNFRSF21  BIRC6  CTSS  RFX5  CD160  MCL1  TNFSF18  TNFSF4  FASLG  IL10  TGFB2  PTGS2  CD48  CD244  MYC  FADD  TNFSF10  BCL6  BIRC2  BIRC3  SCAF11  CASP12  CASP4  CASP1  CASP5  CIITA  SOCS1  TUBA1A  NOS1  APAF1  ALB  CXCL8  CXCL5  IFI30  JAK3  RFXANK  CALR  ICOSLG  IFNAR1  IFNAR2  IDO1  IDO2  JAK2  CD274  PDCD1LG2  IL33  PSME1  PSME2  RIPK3  GZMH  GZMB  LGALS3  LGMN  ARG2  TGFB3  TNFSF14  CD70  TNFSF9  TMIGD2  THOP1  GZMM  TRAF2  PTGS1  ENDOG  TNFSF15  SEC61B  CTSL  FURIN  MFGE8  CD276  LGALS1  ADORA2A  BID  CADM1  CRTAM  B3GAT1  CTNNB1  BAD  HRAS  PDIA3  B2M  CANX  HAVCR2  CD74  CSF2  IL13  IL4  GZMA  GZMK  TSLP  NLN  ERAP1  ERAP2  LNPEP  BCL2  CD226  CASP3  LAP3  CASP6  TDO2  MARCH1  NLRC5  CCL22  MLKL  TRADD  PSMB10  TNFSF12  ALOX12B  ALOX15B  TNFRSF10B  TNFRSF10C  TNFRSF10A  TNFRSF10D  SEC61A2  CXCL12  MARCH8  VSIR  PRF1  CASP7  ENTPD1  FAS  PTEN  IFNB1  IFNA7  IFNA17  IFNA1  IFNA2  IFNA8  CTLA4  ICOS  CD28  CFLAR  CASP10  CASP8  STAT1  MARCH4  PDCD1  TPP2  RFXAP  NT5E  ARG1  IFNGR1  ULBP3  RAET1L  RAET1E  ULBP2  RAET1G  ULBP1  VTCN1  NRAS  CSF1  NRDC  JAK1  BCL10  TNFRSF18  TNFRSF4  TNFRSF14  DFFB  DFFA  TNFRSF9  TNFRSF25  CASP9  TNFRSF1B  MARCH9  IFNG TNFRSF6B  BIRC7  CD40  BCL2L1  EBAG9  CCL28  SIRPA  KRAS  IL6  CYCS  PVRIG  NOS3  CASP2  KLRB1  KLRD1  KLRG1  KLRF1  KLRC1  KLRC2  KLRK1  CD27  TAPBPL  TNFRSF1A  LAG3  GAPDH  BTLA  CD200  CD200R1  CD96  NECTIN3  TIGIT  CD47  HHLA2  CD86  CD80  SEC61A1  CCL5  CCL2  CCL3  LGALS9  NOS2  PSME3  BIRC5  MPO  CSF3  TNFRSF12A  LILRB1  KIR3DL3  KIR2DL3  LILRB2  BIRC8  KIR2DL1  KIR2DL4  KIR3DL2  KIR3DL1  BAX  CEACAM1  CXCL17  TGFB1  NECTIN2  PVR  PSMB9  TAP1 SERPINB9  RIPK1  VEGFA  TNFRSF21  BIRC6  CTSS  RFX5  CD160  MCL1  TNFSF18  TNFSF4  FASLG  IL10  TGFB2  PTGS2  CD48  CD244  MYC  FADD  TNFSF10  BCL6  BIRC2  BIRC3  SCAF11  CASP12  CASP4  CASP1  CASP5  CIITA  SOCS1  TUBA1A  NOS1  APAF1  ALB  CXCL8  CXCL5  IFI30  JAK3  RFXANK  CALR  ICOSLG  IFNAR1  IFNAR2  IDO1  IDO2  JAK2  CD274  PDCD1LG2  IL33  PSME1  PSME2  RIPK3  GZMH  GZMB  LGALS3  LGMN  ARG2  TGFB3  TNFSF14  CD70  TNFSF9  TMIGD2  THOP1  GZMM  TRAF2  PTGS1  ENDOG  TNFSF15  SEC61B  CTSL  FURIN  MFGE8  CD276  LGALS1  ADORA2A  BID  CADM1  CRTAM  B3GAT1  CTNNB1  BAD  HRAS  PDIA3  B2M  CANX  HAVCR2  CD74  CSF2  IL13  IL4  GZMA  GZMK  TSLP  NLN  ERAP1  ERAP2  LNPEP  BCL2  CD226  CASP3  LAP3  CASP6  TDO2  MARCH1  NLRC5  CCL22  MLKL  TRADD  PSMB10  TNFSF12  ALOX12B  ALOX15B  TNFRSF10B  TNFRSF10C  TNFRSF10A  TNFRSF10D  SEC61A2  CXCL12  MARCH8  VSIR  PRF1  CASP7  ENTPD1  FAS  PTEN  IFNB1  IFNA7  IFNA17  IFNA1  IFNA2  IFNA8  CTLA4  ICOS  CD28  CFLAR  CASP10  CASP8  STAT1  MARCH4  PDCD1  TPP2  RFXAP  NT5E  ARG1  IFNGR1  ULBP3  RAET1L  RAET1E  ULBP2  RAET1G  ULBP1  VTCN1  NRAS  CSF1  NRDC  JAK1  BCL10  TNFRSF18  TNFRSF4  TNFRSF14  DFFB  DFFA  TNFRSF9  TNFRSF25  CASP9  TNFRSF1B  MARCH9  IFNG Supplementary Figure 9 Supplementary Table 1   ADORA2A  CASP8  CXCL8  HRAS  KRAS  PTEN  TNFRSF14   AIFM1  CASP9  CYCS  ICOS  LAG3  PTGS1  TNFRSF18   ALOX12B  CCL2  DFFA  ICOSLG  LAP3  PTGS2  TNFRSF1A   ALOX15B  CCL22  DFFB  IDO1  LGALS1  PVR  TNFRSF1B   APAF1  CCL28  EBAG9  IDO2  LGALS3  PVRIG  TNFRSF21   ARG1  CCL3  ENDOG  IFI30  LGALS9  RAET1E  TNFRSF25   ARG2  CCL5  ENTPD1  IFNA1  LGMN  RAET1G  TNFRSF4   B2M  CD113  ERAP1  IFNA17  LILRB1  RAET1L  TNFRSF6B   B3GAT1  CD160  ERAP2  IFNA2  LILRB2  RFX5  TNFRSF9   BAD  CD200  FADD  IFNA7  LNPEP  RFXANK  TNFSF10   BAX  CD200R1  FADD  IFNA8  LTA  RFXAP  TNFSF10   BCL10  CD226  FAS  IFNAR1  MARCH1  RIPK1  TNFSF12   BCL2  CD244  FASLG  IFNAR2  MARCH4  RIPK3  TNFSF14   BCL2L1  CD27  FASLG  IFNB1  MARCH8  SCAF11  TNFSF15   BCL6  CD274  FURIN  IFNG  MARCH9  SEC61A1  TNFSF18   BID  CD276  GZMA  IFNGR1  MCL1  SEC61A2  TNFSF4   BIRC2  CD28  GZMB  IL10   MFGE8   SEC61B  TNFSF9   BIRC3  CD40  GZMH  IL13  MICA  SEC61G  TPP2   BIRC5  CD40LG  GZMK  IL33  MICB  SERPINB9 TRADD   BIRC6  CD47  GZMM  IL4  MLKL  SIRPA  TRAF2   BIRC7  CD48  HAVCR2  IL6  MYC  SOCS1  TSLP   BIRC8  CD70  HHLA2  JAK1  NECTIN2  STAT1  ULBP1   BTLA  CD74  HLA-A  JAK2  NLN  TAP1  ULBP2   BTN1A1  CD80  HLA-B  JAK3  NLRC5  TAP2  ULBP3   BTN2A2  CD86  HLA-C  KIR2DL1  NOS1  TAPBP  VEGFA   BTN3A1  CD96  HLA-DMA  KIR2DL3  NOS2  TAPBPL  VTCN1   BTNL2  CEACAM1  HLA-DMB KIR2DL4  NOS3  TDO2  XIAP   C10orf54  CFLAR  HLA-DOA  KIR2DS1  NRAS  TGFB1   CADM1  CIITA  HLA-DOB  KIR3DL1  NRDC  TGFB2   CALR  CRTAM  HLA-DPA1 KIR3DL2  NT5E  TGFB3   CANX  CSF1  HLA-DPB1 KIR3DL3  PDCD1  THOP1   CASP1  CSF2  HLA-DQA1 KIR3DL4  PDCD1LG2 TIGIT   CASP10  CSF3  HLA-DQA2 KIR3DS1  PDIA3  TMIGD2   CASP12  CTLA4  HLA-DQB1 KLRB1  PRF1  TNF   CASP2  CTNNB1  HLA-DRA  KLRC1  PSMB10  TNF   CASP3  CTSL  HLA-DRB1 KLRC2  PSMB8  TNFRSF10A   CASP4  CTSS  HLA-E  KLRD1  PSMB9  TNFRSF10B   CASP5  CXCL12  HLA-F  KLRF1  PSME1  TNFRSF10C   CASP6  CXCL17  HLA-G  KLRG1  PSME2  TNFRSF10D   CASP7  CXCL5  HLA-G  KLRK1  PSME3  TNFRSF12A 
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